


### Instructions for Use

Labmaster LUCIA<sup>™</sup> SARS-CoV-2 IgG NP Kit for Whole Blood Samples





### Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit for Whole Blood Samples Product Number: I M176

### 1. Intended Use

The Labmaster LUCIA™ SARS-CoV-2 IgG NP test is meant for in vitro diagnostic qualitative detection of the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein (NP) recognizing immunoglobulin G (IgG) antibodies from lithiumheparin whole blood samples in near-patient testing.

The SARS-CoV-2 IgG NP test kit is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2. Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms (i). The SARS-CoV-2 IgG NP test should not be used to diagnose or exclude acute SARS-CoV-2 infection, for measuring immune response related to mRNA-based vaccinations or use as sole basis for patient management decisions.

The Labmaster LUCIA SARS-CoV-2 IgG NP test kit is to be used with semi-automated Labmaster LUCIA™ Analyzer by healthcare professionals.

### **Clinical Significance and Summary of the Test**

The Labmaster LUCIA™ SARS-CoV-2 IgG NP is a serological test used to identify the presence of IgG antibodies against the N-protein of SARS-CoV-2 in whole blood samples. The presence of antibodies against SARS-CoV-2 pathogen (N-protein) in blood indicates adaptive immune response to recent or prior infection. Antibody responses to SARS-CoV-2 can be detected in most individuals 10-15 days after the onset of COVID-19 symptoms (i).

Unit	Sample Volume	Sample Type	Measuring Time
U	7 μL	Whole blood	6 minutes

### **Principle and Procedure**

The Labmaster LUCIA™ SARS-CoV-2 IgG NP test is based on the formation of immunochemical complex between SARS-CoV-2 NP and anti-SARS-CoV-2 IgGs. The anti-SARS-CoV-2 IgGs from the sample bind to the SARS-CoV-2 NP solid phase on the silicon chip on the LUCIA Cassette. The bound IgGs are stained using lanthanide-labeled secondary antibodies.

After the reaction, the unbound excess of the labeled antibodies is separated with automated washing step. The formed antibody-antigen complex is excited with electricity. Resulting electrochemiluminescence is measured. The on-board microprocessor calculates the presence of the analyte in the sample based on a pre-programmed calibration. The calculated result is displayed on the screen of the Labmaster LUCIA™ Analyzer.

### 4. Kit Components

### Contents of the Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit for Whole Blood Samples

Component Name	Product Number LM176 (40 SARS-CoV-2 IgG NP tests)
SARS-CoV-2 IgG NP Cassette*	40 pcs
SARS-CoV-2 IgG NP Dilution Tube for Whole Blood sample**	0.84 mL x 40 pcs
Li-Heparin coated capillaries (7 μL)	2 x 50 pcs
Plungers for capillaries	2 x 50 pcs
NP Instructions for Use and Quick Guide (see centrefold)	1 pc
SARS-CoV-2 IgG NP NFC Card	1 pc

<sup>\*</sup>Contains Tween, sodium borate, sodium azide, bovine serum albumin, bovine gamma globulin

### Materials Required but Not Provided with the Kit

Product Name	Product Number
Labmaster LUCIA™ Analyzer	LM26
Labmaster LUCIA™ Analyzer Instructions for Use	LM28
Lancets for fingertip blood sample	N/A

### Storage

Store the Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit at +2 - +8 °C.

### Description of the Labmaster LUCIA™ SARS-CoV-2 IgG NP Cassette




Figure 1. Labmaster LUCIA™ SARS-CoV-2 IgG NP Cassette

<sup>\*\*</sup>Contains Tween, bovine serum albumin, bovine gamma globulin, sodium azide

### **Warnings and Precautions**

### Health and Safety Information

- For in vitro diagnostic use only.
- The kit should only be used by adequately trained personnel e.g., healthcare professional with formal education in a relevant healthcare or medical field.
- Wear protective clothing and single use laboratory gloves when handling the samples or performing the test. Wash hands properly after performing the test.
- Avoid contact of liquids with eyes and skin. If exposed, rinse immediately with plenty of water.
- All patient samples and controls should be handled as potentially infectious material.
- Liquid reagents contain < 0.1 % sodium azide, which is not considered a harmful amount.
- Washing/measuring buffer contains < 2 % borate, which is not considered a harmful amount.
- Cassette packaging contains a desiccant. This material shall not be used in the assay. Discard the desiccant.
- Disposal: See section 13.

### Analytical Precautions

- The Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit must be used only with the Labmaster LUCIA™ Analyzer.
- Do not use kit components after the expiry date printed on the kit label.
- Do not mix components with other kit batches.
- The NFC Card is batch specific and should be used only for the Labmaster LUCIA™ SARS-CoV-2 IgG NP tests from the same kit batch. If the NFC Card is lost, a new card can be requested at support@labmaster.fi.
- · Cassettes, dilution tubes, capillaries and plungers are for single use. Do not use already used cassettes, dilution tubes, capillaries or plungers.
- The Labmaster LUCIA™ SARS-CoV-2 IgG NP Cassette should not be used if the cassette pouch is damaged or broken, if the foil seal in a cassette ampoule is broken and washing/measuring buffer has leaked from ampoule, or if there is crystal formation on the cassette. Please see section 16.
- Check that there are no air bubbles or foam in the cassette ampoule before use. If there are air bubbles, try to remove the bubbles by turning the cassette upside down or tapping the ampoule gently. If the liquid in the ampoule has foamed, do not use the cassette.
- Use the cassette immediately after cassette pouch has been opened.
- The measurement result is unreliable, if there is a large air bubble which covers the whole surface of the silicon chip of the cassette or if the chip is covered by the foil seal after the measurement.
- Do not use components of the Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit if they have not been stored as instructed in this kit insert.
- Avoid contaminating the Labmaster LUCIA<sup>™</sup> Analyzer.
- There is a possibility that other substances and/or factors may interfere with the test and cause erroneous results (e.g. technical or procedural errors).

### 6. Sample Material and Collection

Sample Material	Sample Volume	Sample Collection
Fingertip sample (whole blood)	7 μL	Prick a clean and dry fingertip with a lancet and wipe away the first drop of blood. Aspirate the sample using a capillary, see section 7, Sample Dilution. The collected fingertip whole blood sample must be used immediately.
Anticoagulated whole blood	7 μL	Use venous blood sample collected in a tube containing Li-heparin. Mix whole blood by inverting the tube several times. Collect the sample using a capillary, see section 7, Sample dilution. The collected whole blood sample must be used immediately.

### 7. Procedure



**NOTE:** Immediately use the kit components taken to room temperature.

NOTE: Each Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit contains one batch specific NFC Card which is used for all the tests in one kit. Before measurement, ensure that NFC Card batch information corresponds to Labmaster LUCIA™ SARS-CoV-2 IgG NP Cassette and SARS-CoV-2 IgG NP Dilution Tube Batch codes.

### Sample Dilution

Place the plunger inside the capillary tube from the end marked with the colour blue.



- Fill the capillary with the sample up to the white stopper (see quick guide, step 1). Ensure that there are no air bubbles in the capillary.
- Place the capillary with sample into the SARS-CoV-2 IgG NP Dilution Tube (see quick guide, step 2).
- Dispense the sample into the buffer by pressing the plunger all the way down. Make sure that the capillary is completely empty.
- Close the cap and mix the diluted sample by inverting the sample tube at least 5 times upside down. Do not shake the sample tube.
- The sample is now ready to be measured.
- The diluted sample must be measured immediately after preparation.

### Measurement

Open the pouch containing the Labmaster LUCIA™ SARS-CoV-2 IgG NP Cassette and check that there are no air bubbles or foam in the cassette ampoule before sample application. If there are air bubbles, try to remove the bubbles by turning the cassette upside down or tapping the ampoule gently. If the liquid in the ampoule has foamed, do not use the cassette. After the cassette ampoule has been checked and there are not small air bubbles or foam, use it immediately.

- Select the Patient sample measurement icon on LUCIA Analyzer's display, enter patient ID and read the NFC Card as instructed in Labmaster LUCIA™ Instructions for Use (see quick quide, step 3).
- Slide the cassette on the tray of the analyzer from the right side of the tray (see guick quide, step 4). Note that the diluted sample has to be dispensed into the cassette during the 1-minute sample application time after the NFC Card has been read.
- Fill the capillary (7 µL) with the diluted sample up to the white stopper (see quick guide, step 5). Ensure that there are no air bubbles in the capillary.
- Place the capillary into the sample application hole of the cassette and hold the capillary against the membrane (see quick guide, step 6). Apply the sample by pressing the plunger all the way down. Hold the capillary against the membrane until the sample has spread on the entire membrane.
- Start the measurement by selecting the Accept icon on the display (see quick guide, step 7). The measurement time is 6 minutes.
- When the measurement has been completed, the results will be shown on the display and the cassette will come out of the analyzer (see quick guide, step 8).
- If silicon chip of the cassette is covered by large air bubble, membrane or by foil, do not use the result.
- Dispose of the cassette immediately after use.
- Place the NFC Card back into the kit box.



See the Labmaster LUCIA™ Analyzer's Instructions for Use for more detailed measurement instructions.

### **Quality Control**

Both the Labmaster LUCIA™ Analyzer and Labmaster LUCIA™ SARS-CoV-2 IgG NP test are factory calibrated. It is recommended to use commercial SARS-CoV-2 IgG controls for quality assurance. This kit is meant for whole blood samples. Dilution tubes and instructions for handling serum and plasma-based controls are available at Labmaster separately. The user sets the acceptance limit values for the controls.

### Interpretation of Results 9.

When interpreting the Labmaster LUCIA™ SARS-CoV-2 IgG NP test results, take into consideration the patient's medical history, clinical examinations and other laboratory results.

Result	Interpretation
< 1.000 U	Negative for SARS-CoV-2 IgG NP antibodies
≥ 1.000 U	Positive for SARS-CoV-2 IgG NP antibodies

### 10. Limitations of the Procedure

Follow the sample collection, dilution and assay procedures specified in these instructions, otherwise the results might not be reliable. The result is only for clinical reference and should never be the sole basis for making a diagnosis. A clinical decision is always required.

The Labmaster LUCIA™ SARS-CoV-2 IgG NP Kit is intended to be used as an aid in identifying immune response related to SARS-CoV-2. The result is only for clinical reference and should never be the sole basis for making a diagnosis. A clinical decision is always required.

The Labmaster LUCIA™ SARS-CoV-2 IgG NP test should not be used to diagnose or exclude acute SARS-CoV-2 infection. The test is not intended for determination of the infective disease status: it does not provide information on state, evolution or severity of the COVID-19 disease. The test is not intended for measuring immune response related to mRNA-based vaccinations. The test is not intended for monitoring of levels of medicinal products, substances or biological components. The test is intended for people who have been exposed to SARS-CoV-2.

Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d after the onset of COVID-19 symptoms (i). IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the post infection duration of antibodies presence is not well characterized.

A negative result should be treated as presumptive. Both positive and negative results should be considered in relation to patient's exposure history and other symptoms consistent with COVID-19.

Heterophilic antibodies in human blood are a well-recognized source of interference in immunoassays. They may react with immunoglobulins included in the assay components. Samples from patients routinely exposed to animals or animal serum products can demonstrate this type of interference potentially causing anomalous results (ii).

### 11. Performance Characteristics

### Clinical Performance

Clinical performance was evaluated with 62 lithium-heparin whole blood samples measured with Labmaster LUCIA™ SARS-CoV-2 IgG NP test and comparative method in-house SARS-CoV-2 N and S1 based EIA at University of Turku (vii).

Seronegative samples (n)	42	Negative agreement	100%
Seropositive samples (n)	20	Positive agreement	77%
Total (n)	62	Overall agreement	90%

# LABMASTER

A Point-of-care platform based on patented CECL technology

### LABMASTER Ltd

Rauhalinnantie 31,

20780 Kaarina, Finland | Tel. +358 22 760 555 www.labmaster.fi | E-mail: support@labmaster.fi


## LABMASTER medical devices





Labmaster LUCIA™ Analyzer

40 cassettes, 40 tubes, 100 capillaries, 100

for Whole Blood Samples. Contents:









### Precision

The precision of the Labmaster LUCIA™ SARS-CoV-2 IgG NP test was determined applying the CLSI guidelines EP12-A2 (iii) EP05-A3 (iv). Two whole blood sample levels (Low <1.000 U and High ≥1.000 U) were measured as 5 replicates, 3 times (runs) a day, during 1 day, using 3 different Labmaster LUCIA™ Analyzers and 3 cassette lots (total n=45/sample).

Sample	Mean result	Repeat	ability	Betwee	en-Run	Betw Analy Casset	yzer/	Witi Labor	
	(U)	SD	CV%	SD	CV%	SD	CV%	SD	CV%
Low	0.5	0.20	40	0.05	10	0.05	9	0.21	42
High	5.6	1.01	18	0.21	4	0.67	12	1.23	22

### Cross-reactivity

Analytical specificity of SARS-CoV-2 IgG NP test kit was determined by testing 4 serum/ plasma patient samples, each containing multiple potentially cross-reacting IgGs. Each of the 4 samples was measured as 6 replicates. The analytical specificity claim is that there is no cross-reactivity from the 17 substances listed.

Containing IgG towards	N	Negative	Positive
Human coronavirus HKU1	6	6	0
Human coronavirus OC43	6	6	0
Human coronavirus 229E	6	6	0
Human coronavirus NL63	6	6	0
Haemophilus influenzae	18	18	0
Respiratory syncytial virus (RSV)	18	18	0
Influenza A	6	6	0
Influenza B	18	18	0
Parainfluenza 1-4	18	18	0
Adenovirus	6	6	0
Enterovirus	12	12	0
Mycoplasma pneumoniae	18	18	0
Legionella	6	6	0
Chlamydia pneumoniae	6	6	0
Epstein–Barr virus	6	6	0
Hepatitis B	6	6	0
Bordetella pertussis	18	18	0
Total	180	180	0

### Interfering Substances

Interference was evaluated in alignment with CLSI guideline EP07-A3 (v), CLSI EP37 (VIITE) and 'Current performance of COVID-19 methods and devices and proposed performance criteria – Working document of Commission services' (vi). Potentially interfering substances (added concentration of tested substance in column Claim) were tested in lithium heparin blood with one analyte level (approx. 6 U). IgG was found to interfere at concentrations above 5.5 g/L. Other tested substances did not interfere at tested concentrations. All test concentrations are in addition to endogenous level in blood.

Substance	Claim
Haemoglobin	No interference found up to 10 g/L
Triglycerides	No interference found up to 33 g/L
Bilirubin, conjugated	No interference found up to 400 mg/L
Bilirubin, unconjugated	No interference found up to 400 mg/L
IgG	No interference up to 5.5 g/L. 40–60% decreased result with concentrations $> 5.5 - 20$ g/L.
Acetylsalicylic acid	No interference found up to 700 mg/L
Ibuprofen	No interference found up to 500 mg/L

### 12. Traceability

The Labmaster LUCIA™ SARS-CoV-2 IgG NP test is traceable to WHO 20/136 1st International Standard Anti-SARS-CoV-2 Immunoglobulin (human).

### 13. Disposal

All patient samples and materials shall be disposed of according to local laws and regulations. All samples, used cassettes, capillaries, plungers and dilution tubes shall be disposed of as biological, potentially infectious materials. Paper, carton and pouches can be recycled according local and national instructions. Desiccants and the NFC card can be disposed of in general waste. This product will not cause any health risk if used in accordance with the Instructions for Use.

### 14. Notice on Reporting Serious Incidents

For a patient/user/third party in the European Union and in countries with identical regulatory regime (Regulation 2017/746/EU on In vitro Diagnostic Medical Devices); if, during the use of this device or as a result of its use, a serious incident has occurred, please report it to the manufacturer and/or its authorized representative and to your national authority.

### 15. Warranty

The performance data presented here was obtained using the assay procedure indicated. Any change or modification of the procedure not recommended by Labmaster Ltd. may affect the results. In which event it disclaims all warranties expressed, implied or statutory including the implied warranty of merchantability and fitness for use and shall not be liable for damages indirect or consequential.

### 16. Troubleshooting

For Analyzer-related questions see Labmaster LUCIA™ Analyzer (LM26) Instructions for Use (LM28).

Indication	Probable Causes	Corrective Action	
<ul> <li>Washing/measuring buffer has leaked from ampoule or there is crystal formation on the cassette.</li> </ul>	Foil seal in the cassette ampoule has broken.	<ul> <li>Do not use the cassette.</li> <li>If the problem reoccurs, contact support@labmaster.fi.</li> </ul>	
Washing/measuring buffer has foamed.	Cassette has been handled heavy-handedly or cassette has been dropped.	Do not use the cassette.     If the problem reoccurs, contact support@labmaster.fi.	
Sample does not go through the membrane.	<ul> <li>Kit has not been stored at the instructed storage conditions or the cassette pouch has broken.</li> <li>Cassette has been taken out of the pouch too early.</li> </ul>	<ul> <li>Do not use the cassette.</li> <li>If the problem reoccurs, contact support@labmaster.fi.</li> </ul>	
Liquid residue on the tray.	Washing/measuring buffer has leaked from ampoule.	<ul> <li>Blot the liquid into soft paper or cloth.</li> <li>If the problem reoccurs, contact support@labmaster.fi.</li> </ul>	
Rejected measurement.	<ul> <li>Air bubble or foil seal on top of silicon chip during measurement.</li> <li>Air bubbles or foam in washing/measuring buffer.</li> </ul>	<ul> <li>Repeat the measurement using a new cassette.</li> <li>If the problem reoccurs, contact support@labmaster.fi.</li> </ul>	
Grinding sound during tray movement.	<ul> <li>Mechanical malfunction.</li> <li>Cassette is placed on the tray incorrectly.</li> </ul>	<ul> <li>Restart the analyzer.</li> <li>Repeat the measurement using a new cassette.</li> <li>If the problem reoccurs, contact support@labmaster.fi.</li> </ul>	
Foil seal covers the silicon chip after measurement.	Defective cassette.	<ul> <li>Measurement result is unreliable, do not use the result.</li> <li>Repeat the measurement using a new cassette.</li> <li>If the problem reoccurs, contact support@labmaster.fi.</li> </ul>	

### 17. References

- Seow J, Graham C, Merrick B et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology 5(12), 1598-1607 (2020). https://doi.org/10.1038/ s41564-020-00813-8.
- Clinical and Laboratory Standards Institute (CLSI) guideline I/LA30-A. ii.
- Clinical and Laboratory Standards Institute (CLSI) guideline EP12-A2. iii.
- iv. Clinical and Laboratory Standards Institute (CLSI) guideline EP05-A3.
- V. Clinical and Laboratory Standards Institute (CLSI) guideline EP07-A3.
- vi. Current performance of COVID-19 test methods and devices and proposed performance criteria - Working document of Commission services.
- vii. Jalkanen, P., Kolehmainen, P., Häkkinen, H.K. et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun 12, 3991 (2021). https://doi.org/10.1038/s41467-021-24285-4

### 18. Explanation of Symbols

Symbol	Description
CE	The CE marking Conformity to the European directive 98/79/EC on in vitro diagnostic medical devices
	Manufacturer
	Use by date (YYYY-MM-DD)
	Temperature limit
	Do not reuse
i	Consult Instructions for Use
REF	Catalog number
LOT	Batch code
IVD	In vitro Diagnostic medical device
Σ	Contents sufficient for <n> tests</n>
<u> </u>	Caution



